External imaging of CCND1, MYC, and KRAS oncogene mRNAs with tumor-targeted radionuclide-PNA-peptide chimeras

Annals of the New York Academy of Sciences

Volumn 1059, Issue , 2005, Pages 106-144

  Tian, Xiaobing ^a,b   Chakrabarti, Atis ^a,b   Amirkhanov, Nariman V ^a,b   Aruva, Mohan R ^a   Zhang, Kaijun ^a   Mathew, Boby ^a   Cardi, Christopher ^a,b   Qin, Wenyi ^c   Sauter, Edward R ^c   Thakur, Mathew L ^a,b   Wickstrom, Eric ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c University of Missouri   (United States)

Author keywords

Antisense; Breast cancer; Chelators; Conjugates; Gene expression; Hybridization; Imaging; Noninvasive; Oligonucleotides; Oncogenes; Pancreatic cancer; Peptides; Positron emission; Radionuclides; Scintigraphy; Tumors

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CCND1 PROTEIN; CHELATING AGENT; COPPER 64; CYCLIN D1; ESTROGEN RECEPTOR; K RAS PROTEIN; MESSENGER RNA; MYC PROTEIN; ONCOPROTEIN; PEPTIDE DERIVATIVE; PEPTIDE NUCLEIC ACID; RADIOISOTOPE; SOMATOMEDIN C RECEPTOR; TECHNETIUM 99M; UNCLASSIFIED DRUG; WT 4113; WT 4172; WT 4185; WT 4219; WT 4235; WT 4351; WT 4361; WT 4433; WT 990;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SCINTISCANNING; CANCER SCREENING; CANCER STAGING; CARBOXY TERMINAL SEQUENCE; CCND1 GENE; CELL STRAIN MCF 7; CHIMERA; CLINICAL EXAMINATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG TARGETING; EARLY DIAGNOSIS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYBRIDIZATION; MAMMOGRAPHY; MOUSE; MULTIMODALITY CANCER THERAPY; NON INVASIVE MEASUREMENT; NONHUMAN; ONCOGENE; ONCOGENE K RAS; ONCOGENE MYC; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE DISTRIBUTION; SCID MOUSE; SOLID TUMOR; SURVIVAL RATE; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; UNITED STATES;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS;

EID: 32244445806     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1339.038     Document Type: Conference Paper

References (70)

1. FONG, L.Y. et al. 2000. Muir-Torre-like syndrome in Fhit-deficient mice. Proc. Natl. Acad. Sci. USA 97: 4742-4747.
2. BISHOP, J.M. 1991. Molecular themes in oncogenesis. Cell 64: 235-248.
3. HILGERS, W. & S.E. KERN. 1999. Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer 26: 1-12.
4. KNUDSON, A.G., JR. 1970. Genetics and cancer. Postgrad. Med. 48: 70-74.
5. WOOSTER, R. 2000. Cancer classification with DNA microarrays. Is less more? Trends Genet. 16: 327-329.
6. PEROU, C.M. et al. 1999. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. USA 96: 9212-9217.
7. ALIZADEH, A., et al. 1998. Probing lymphocyte biology by genomic-scale gene expression analysis. J. Clin. Immunol. 18: 373-379.
8. BARLUND, M. et al. 2000. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst. 92: 1252-1259.
9. CLARK, E.A. et al. 2000. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532-535.
10. PEROU, C.M. et al. 2000. Molecular portraits of human breast tumours. Nature 406: 747-752.
11. AMERICAN CANCER SOCIETY. 2005. Cancer Facts and Figures. Atlanta, GA.
12. ROSENBERG, R.D. et al. 1998. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology 209: 511-518.
13. DIEKMANN, F. et al. 2004. Evaluation of a wavelet-based computer-assisted detection system for identifying microcalcifications in digital full-field mammography. Acta Radiol. 45: 136-141.
14. FAHY, B.N. et al. 2001. Cost-benefit analysis of biopsy methods for suspicious mammographic lesions. Arch. Surg. 136: 990-994; discussion 994-995.
15. EVANS, D.B., J.L. ABBRUZZESE & C.G. WILLETT. 2001. Cancer of the pancreas. In Cancer: Principles and Practice of Oncology. V.T. DeVita, S. Hellman & S.A. Rosenberg, Eds.: 1126-1161. Lippincott, Williams & Wilkins. Philadelphia.
16. SAUTER, E.R. et al. 2000. Prolonged response to antisense cyclin D1 in a human squamous cancer xenograft model. Clin. Cancer Res. 6: 654-660.
17. TIAN, X. et al. 2004. External imaging of CCND1 cancer gene activity in experimental human breast cancer xenografts with Tc-99m-peptide-PNA-peptide chimeras. J. Nucl. Med. 45: 2070-2082.
18. VAUGHN, J.P. et al. 1995. Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc. Natl. Acad. Sci. USA 92: 8338-8342.
19. WICKSTROM, E. & F.L. TYSON. 1997. Differential oligonucleotide activity in cell culture versus mouse models. Oligonucleotides as therapeutic agents. Ciba Found. Symp. 209: 124-137; discussion 137-141.
20. ANDREWS, D.W. et al. 2001. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J. Clin. Oncol. 19: 2189-2200.
21. WICKSTROM, E.L. et al. 1988. Human promyelocytic leukemia HL-60 cell proliferation and c-Myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-MYC mRNA. Proc. Natl. Acad. Sci. USA 85: 1028-1032.
22. WICKSTROM, E., T.A. BACON & E.L. WICKSTROM. 1992. Down-regulation of c-Myc antigen expression in lymphocytes of Eμ-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res. 52: 6741-6745.
23. HUANG, Y. et al. 1995. Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate. Mol. Med. 1: 647-658.
24. SMITH, J.B. & E. WICKSTROM. 1998. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model. J. Natl. Cancer Inst. 90: 1146-1154.
25. AOKI, K. et al. 1995. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res. 55: 3810-3816.
26. KAWADA, M. et al. 1997. Inhibition of anchorage-independent growth of ras-transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed against K-ras. Biochem. Biophys. Res. Commun. 231: 735-737.
27. OKADA, F. et al. 1998. Impact of oncogenes in tumor angiogenesis: mutant K-ras upregulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells Proc. Natl. Acad. Sci. USA 95: 3609-3614.
28. KITA, K. et al. 1999. Growth inhibition of human pancreatic cancer cell lines by antisense Oligonucleotides specific to mutated K-ras genes. Int. J. Cancer 80: 553-558.
29. COGOI, S. et al. 2004. Antiproliferative activity of a triplex-forming oligonucleotide recognizing a Ki-ras polypurine/polypyrimidine motif correlates with protein binding. Cancer Gene Then 11: 465-476.
30. BISHOP, M.R. et al. 1997. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. J. Hematother. 6: 441-446.
31. BAYEVER, E. et al. 1994. Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leukemia & Lymphoma 12: 223-231.
32. BRADLEY, J.D. et al. 2004. Implementing biologic target volumes in radiation treatment planning for non-small cell lung cancer. J. Nucl. Med. 45: 96S-101S.
33. NAMAVARI, M. et al. 2000. Synthesis of 8-[(18)F]fluoroguanine derivatives: in vivo probes for imaging gene expression with positron emission tomography. Nucl. Med. Biol. 27: 157-162.
34. PONOMAREV, V. et al. 2000. PET imaging of p53 gene expression in tumors. J. Nucl. Med. 41: 263P-264P.
35. LEYTON, J. et al. 2005. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 65: 4202-4210.
36. EISENHUT, M. & U. HABERKORN. 2000. [123I]VIP receptor scintigraphy in patients with pancreatic adenocarcinomas. Eur. J. Nucl. Med. 27: 1589-1590.
37. GOLD, D.V. et al. 2001. Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Crit. Rev. Oncol. Hematol. 39: 47-154.
38. WICKSTROM, E. 1992. Strategies for administering targeted therapeutic oligodeoxynucleotides. Trends Biotechnol. 10: 281-287.
39. GRAY, G.D., S. BASU & E. WICKSTROM. 1997. Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3′-alkylamino oligodeoxynucleotides, 2′-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids. Biochem. Pharmacol. 53: 1465-1476.
40. WALDER, R.Y. & J.A. WALDER. 1988. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 85: 5011-5015.
41. AGRAWAL, S. 1996. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 14: 376-387.
42. BUCHARDT, O. et al. 1993. Peptide nucleic acids and their potential applications in biotechnology. Trends Biotechnol. 11: 384-386.
43. GOOD, L. & P.E. NIELSEN. 1997. Progress in developing PNA as a gene-targeted drug. Antisense Nucleic Acid Drug Dev. 7: 431-437.
44. EGHOLM, M. et al. 1993. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 365: 566-568.
45. BONHAM, M.A. et al. 1995. An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Res. 23: 1197-1203.
46. ARMENGOL, G. et al. 2000. DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma. Cancer Genet. Cytogenet. 116: 133-141.
47. PIETRZKOWSKI, Z. et al. 1992. Inhibition of cellular proliferation by peptide analogues of insulin- like growth factor 1. Cancer Res. 52: 6447-6451.
48. BASU, S. & E. WICKSTROM. 1997. Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconjugate Chem. 8: 481-488.
49. 99mTc-labeled fibrin alpha-chain peptide. J. Nucl. Med. 41: 161-168.
50. THAKUR, M.L. et al. 2000. 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J. Nucl. Med. 41: 107-110.
51. 99Tc-VIP analog. J. Nucl. Med. 45: 1381-1389.
52. TIAN, X. & E. WICKSTROM. 2002. Continuous solid-phase synthesis and disulfide cyclization of peptide-PNA-peptide chimeras. Organic Lett. 4: 4013-4016.
53. 99mTc-peptide-peptide nucleic acid probes for imaging oncogene mRNAs in tumours. Nucl. Med. Commun. 24: 857-863.
54. 99mTc]peptide- peptide nucleic acid-peptide chimera. Bioconjugate Chem. 16: 70-79.
55. CHAKRABARTI, A. et al. 2005. Synthesis of novel PNA-peptide chimera for non-invasive imaging of cancer. Nucleosides, Nucleotides & Nucleic Acids 24: 409-415.
56. SCHNEIDER, R.F. et al. 1984. N,N′-bis(S-benzoylmercaptoacetamido) ethylenediamine and propylenediamine ligands as renal function imaging agents. I. Alternate synthetic methods. J. Nucl. Med. 25: 223-229.
57. GARIEPY, J. et al. 2002. A simple two-step approach for introducing a protected diaminedithiol chelator during solid-phase assembly of peptides. Bioconjug. Chem. 13: 679-684.
58. BARTUCCI, M. et al. 2001. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res. 61: 6747-6754.
59. BIÈCHE, I. et al. 2002. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br. J. Cancer 86: 580-586.
60. BIÈCHE, I. et al. 1999. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res. 59: 2759-2765.
61. TAN, M.H. & T.M. CHU. 1985. Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPC-1) implanted orthotopically into nude mice. Tumour Biol. 6: 89-98.
62. YASUDA, D., et al. 1993. Possible association of nm23 gene expression and Ki-ras point mutations with metastatic potential in human pancreatic cancer-derived cell lines. Int. J. Oncol. 3: 641-644.
63. TIAN, X. et al. 2003. Imaging oncogene expression. In Therapeutic Oligonucleotides: Antisense, RNAi, Triple Helix, DNA Decoys, and DNA Chips. N.Y. Acad. Sci. 1002: 1083-1099.
64. STALTERI, M.A. & S.J. MATHER. 2000. In-vitro studies on 99m-Tc-labeled HYNIC-conjugated Oligonucleotides. Nucl. Med. Commun. 21: 374.
65. PALLELA, V.R. et al. 1999. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. J. Nucl. Med. 40: 352-360.
66. JAIN, R.K. 1998. The next frontier of molecular medicine: delivery of therapeutics. Nat. Med. 4: 655-657.
67. HEDBERG, Y. et al. 1999. Cyclin-D1 expression in human renal-cell carcinoma. Int. J. Cancer 84: 268-272.
68. LIPPONEN, P., M. ESKELINEN & K. SYRJANEN. 1995. Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br. J. Cancer 71: 863-867.
69. DE JONG, M. et al. 1996. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J. Nucl. Med. 37: 1388-1392.
70. AMIRKHANOV, N.V. & E. WICKSTROM. 2005. Synthesis of novel polydiamidopropanoate dendrimer PNA-peptide chimeras for non-invasive magnetic resonance imaging of cancer. Nucleosides, Nucleotides & Nucleic Acids 24: 423-426.